Latest Breaking News On - Guillermo garcia manero - Page 13 : comparemela.com

ALX Oncology Announces Initial Data from ASPEN-02, the Ongoing Phase 1 / 2 Study of Evorpacept in Combination with Azacitidine, Demonstrating Safety and Preliminary Activity in Patients with Myelodysplastic Syndrome

ALX Oncology Announces Initial Data from ASPEN-02, the Ongoing Phase 1 / 2 Study of Evorpacept in Combination with Azacitidine, Demonstrating Safety and Preliminary Activity in Patients with Myelodysplastic Syndrome
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

United statesKaren sharmaSophia randolphPeter garciaGuillermo garcia maneroAmerican society of hematologyExchange commissionDepartment of leukemiaMd anderson cancer centerOncology holdings incHost conference callHoldings incAmerican societyAnnual meetingCancer centerChief medical officer

Karyopharm to Host Virtual Investor Day on December 8, 2021

/PRNewswire/ Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it.

Srinivas tantravahiRafael fonsecaRobert colemanCristina gasparettoGuillermo garcia maneroVicky makkerKaryopharm therapeutics incUniversity of utahEuropean commissionMd anderson cancer centerPrnewswire karyopharm therapeutics incDuke university medical centerKaryopharm selective inhibitor of nuclear exportUs oncology researchMemorial sloan kettering cancer centerInvestor day

Curis Announces Positive Updated Data from Ongoing Phase 1/2 Study of CA-4948 Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes

/PRNewswire/ Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today.

United statesJames dentzerGuillermo garcia maneroUniversity of texas md anderson cancer centerDrug administrationEuropean hematology associationCuris incExchange commissionPrnewswire curis incDepartment of leukemiaRoche groupVirtual congressChief executive officerMyelodysplastic syndromesCancer centerRecommended phase

Curis to Host Virtual Event to Discuss Updated Clinical Data for CA-4948 in AML/MDS Presented at EHA

/PRNewswire/ Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today.

United statesJames dentzerGuillermo garcia maneroUniversity of texas md anderson cancer centerEuropean hematology associationDrug administrationCuris incPrnewswire curis incDepartment of leukemiaRoche groupVirtual congressMyelodysplastic syndromesOrphan drug designationஒன்றுபட்டது மாநிலங்களில்கில்லர்மோ கார்சியா மானேரோபல்கலைக்கழகம் ஆஃப் டெக்சாஸ் ம்ட் ஆண்டர்சன் புற்றுநோய் மையம்

Curis Reports Updated Data in Two Abstracts for CA-4948 Accepted for Presentation at the European Hematology Association 2021 Virtual Congress

Share this article Share this article LEXINGTON, Mass., May 12, 2021 /PRNewswire/ Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that two abstracts for CA-4948, a novel, small molecule IRAK4 inhibitor, have been accepted for oral and poster presentation at the European Hematology Association 2021 Virtual Congress (EHA), which will be held virtually from June 9-17, 2021. The abstracts include updated data from a February data-cut for its ongoing open-label, single arm, Phase 1/2 study of CA-4948 in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS). We are very pleased to report this clinical update on our first-in-class IRAK4 kinase inhibitor, CA-4948, as an anticancer agent for patients with acute myeloid leukemia and myelodysplastic syndromes for whom multiple prior lines of therapy have been unsuccessful, said James Dentzer, Presiden

United statesJames dentzerGuillermo garcia maneroUniversity of texas md anderson cancer centerDrug administrationEuropean hematology associationMd anderson cancer centerCuris incExchange commissionDepartment of leukemiaRoche groupVirtual congressBiology translational researchChief executive officerDose escalation trialNovel oral